Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Current Leases (2022 - 2025)

Candel Therapeutics' Current Leases history spans 2 years, with the latest figure at $513000.0 for Q4 2023.

  • On a quarterly basis, Current Leases rose 10.56% to $513000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $513000.0, a 10.56% increase, with the full-year FY2023 number at $513000.0, up 10.56% from a year prior.
  • Current Leases hit $513000.0 in Q4 2023 for Candel Therapeutics, up from $500000.0 in the prior quarter.
  • Over the last five years, Current Leases for CADL hit a ceiling of $513000.0 in Q4 2023 and a floor of $429000.0 in Q1 2022.